Confirmed objective response rate of 44% and median progression-free survival of 6.7 months seen in cohort subset mirroring patient population selected for planned Phase 3 study. Company preparing to meet with FDA in early 3Q2016; targeting initiation of Phase 3 study in 4Q2016.
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences
− Conference call at 8:00 am ET today will include update on mirvetuximab soravtansine, the first folate receptor α (FRα)-targeting antibody-drug conjugate (ADC), including the design of the FORWARD I trial − WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc.
- Proven leader with deep experience building oncology businesses - WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN) a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that Mark J.
Novel CD33-targeting product candidate is the first antibody-drug conjugate (ADC) to employ an IGN, a new type of cancer-killing agent. Phase 1 study in acute myeloid leukemia (AML) is designed to efficiently inform the IMGN779 development pathway. WALTHAM, Mass.
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m.
- Successor Expected to be Announced Shortly - WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN) a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius , age 63, has decided to